TRAIL-R1 is a receptor for the cytotoxic ligand TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappaB.
Binds to human TRAIL receptor 1 (DR4), but not human TRAIL-R2 (DR5). Binding to TRAIL-R3, -R4 and osteoprotegrin (OPG) are not tested.
Sequence:The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to a His-tag and a linker peptide and contains aa substitutions, which generate a binding specificity towards TRAIL receptor 1 (TRAIL-R1; DR4).
Biological Activity:Induces apoptosis in a concentration range of 20-500ng/ml of TRAIL-R1 (DR4) expressing cell lines (e.g. RAMOS). It is inefficient to kill via TRAIL-R2 (DR5) in Jurkat cells. The activity depends on the relative cellular surface expression of TRAIL-R1 compared to other death-signaling TRAIL-Rs. Concentrations of KillerTRAIL™-R1 to induce apoptosis may vary depending on the cell type.
Note: This protein does not require a cross-linking enhancer for its potent biological activity.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
